Forte Biosciences Inc FBRX:NASDAQ

Last Price$1.31Cboe Real-Time Last Sale as of 3:36PM ET 1/27/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.09(6.79%)
Bid (Size)$1.30 (800)
Ask (Size)$1.31 (500)
Day Low / High$1.30 - 1.51
Volume257.4 K
 

View Biotechnology IndustryPeer Comparison as of 01/27/2022

 

Forte Biosciences Inc ( NASDAQ )

Price: $1.31
Change: -0.09 (6.79%)
Volume: 257.4 K
3:36PM ET 1/27/2022
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

Yumanity Therapeutics Inc ( NASDAQ )

Price: $1.77
Change: -0.05 (2.75%)
Volume: 30.6 K
3:22PM ET 1/27/2022
 
 

Pulmatrix Inc ( NASDAQ )

Price: $0.37
Change: -0.03 (7.41%)
Volume: 731.8 K
3:39PM ET 1/27/2022
 
 

Plus Therapeutics Inc ( NASDAQ )

Price: $0.86
Change: -0.006 (0.66%)
Volume: 255.5 K
1:23PM ET 1/27/2022
 

Read more news Recent News

--Chardan Capital Upgrades Forte Biosciences to Neutral From Sell Following Recent Selloff, Adjusts Price Target to $3.50 From $4
9:43AM ET 9/20/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Insider Sell: Forte Biosciences
5:05PM ET 9/08/2021 MT Newswires

Paul A. Wagner, Director, CEO, President, Secretary, and Chair of the Board, on September 07, 2021, sold 1,000,000 shares in Forte Biosciences (FBRX) for...

Top Midday Decliners
2:09PM ET 9/07/2021 MT Newswires

CorMedix (CRMD) said it is facing uncertainty in its resubmission timeline for the DefenCath new drug application after a contract manufacturer encountered...

--Ladenburg Thalmann Downgrades Forte Biosciences to Neutral From Buy
8:04AM ET 9/07/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionForte Biosciences, Inc. is a clinical stage biopharmaceutical company focused on dermatology. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner in 2017 and is headquartered in Torrance, CA. View company web site for more details
AddressMRL Building 3
Torrance, California 90502
Phone+1.310.618.6994
Number of Employees79
Recent SEC Filing01/18/20224
Chairman, President & Chief Executive OfficerPaul A. Wagner
Chief Financial OfficerAnthony A. Riley
Chief Medical Officer & Head-Clinical DevelopmentDaniel J. Burge

Company Highlights

Price Open$1.42
Previous Close$1.40
52 Week Range$1.26 - 43.57
Market Capitalization$19.3 M
Shares Outstanding14.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/23/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.69
Beta vs. S&P 500N/A
Revenue$18.0 M
Net Profit MarginN/A
Return on Equity-44.28%

Analyst Ratings as of 12/26/2021

Buy
0
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset